Literature DB >> 20449578

Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual.

Maria G Vogiatzi1, Jaime Tsay, Kostas Verdelis, Stefano Rivella, Robert W Grady, Stephen Doty, Patricia J Giardina, Adele L Boskey.   

Abstract

Osteoporosis and fractures occur frequently in patients with beta-thalassemias, a group of congenital hemolytic anemias characterized by decreased synthesis of the beta chain of hemoglobin. In this study, we determined the bone abnormalities of the th3 thalassemia mouse, generated by deletion of the mouse beta-chain genes. The heterozygous th3/+ mouse has moderate anemia and serves as a model of beta-thalassemia intermedia, which represents the mild thalassemia phenotype. The th3/th3 mouse has lethal anemia and is a model of beta-thalassemia major, which is characterized by life-threatening anemia requiring regular transfusions to sustain life. Compared to controls, (1) microCT of trabecular bone showed decreased bone volume fraction, number of trabeculae, and trabecular thickness in both th3/+ and th3/th3 (P < 0.05); (2) cortical bone analysis showed thinner cortices and increased marrow area in th3/+ (P < 0.05); (3) microCT abnormalities in th3/+ mice were present by 2 months and did not worsen with age; (4) histomorphometry was significant for decreased bone formation and resorption in both th3/+ and th3/th3, and expression of cathepsin K and osteocalcin from bone of both th3/+ and th3/th3 animals was reduced (P < 0.05); (5) biomechanics showed reduced maximum load, maximum moment, and structural stiffness in both th3/+ and th3/th3 (P < 0.01). In conclusion, the th3 mouse model of thalassemia manifests bone changes reminiscent of those in humans and can be used for further bone studies in thalassemia. Bone changes are associated with decreased bone turnover and develop early during the period of bone accrual.

Entities:  

Mesh:

Year:  2010        PMID: 20449578      PMCID: PMC2917203          DOI: 10.1007/s00223-010-9365-0

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  20 in total

Review 1.  Beta-thalassemia.

Authors:  Deborah Rund; Eliezer Rachmilewitz
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

2.  Prevalence of fractures among the Thalassemia syndromes in North America.

Authors:  M G Vogiatzi; E A Macklin; E B Fung; E Vichinsky; N Olivieri; J Kwiatkowski; A Cohen; E Neufeld; P J Giardina
Journal:  Bone       Date:  2005-11-17       Impact factor: 4.398

3.  A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.

Authors:  Stefano Rivella; Chad May; Amy Chadburn; Isabelle Rivière; Michel Sadelain
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

4.  Bone mineral density in men with genetic hemochromatosis and HFE gene mutation.

Authors:  P Guggenbuhl; Y Deugnier; J F Boisdet; Y Rolland; A Perdriger; Y Pawlotsky; G Chalès
Journal:  Osteoporos Int       Date:  2005-06-01       Impact factor: 4.507

5.  Bone mineral metabolism in adults with beta-thalassaemia major and intermedia.

Authors:  R Dresner Pollack; E Rachmilewitz; A Blumenfeld; M Idelson; A W Goldfarb
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

6.  Spectroscopic characterization of collagen cross-links in bone.

Authors:  E P Paschalis; K Verdelis; S B Doty; A L Boskey; R Mendelsohn; M Yamauchi
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

7.  Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia.

Authors:  Pat Mahachoklertwattana; Vorachai Sirikulchayanonta; Ampaiwan Chuansumrit; Patcharee Karnsombat; Lulin Choubtum; Arporn Sriphrapradang; Somnuek Domrongkitchaiporn; Rojana Sirisriro; Rajata Rajatanavin
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

8.  Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.

Authors:  A L Boskey; L Spevak; R S Weinstein
Journal:  Osteoporos Int       Date:  2008-09-04       Impact factor: 4.507

9.  Abnormalities in bone mineral density and bone histology in thalassemia.

Authors:  Somnuek Domrongkitchaiporn; Vorachai Sirikulchayanonta; Pantep Angchaisuksiri; Wasana Stitchantrakul; Chavasak Kanokkantapong; Rajata Rajatanavin
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

10.  Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture.

Authors:  Samuel Gourion-Arsiquaud; Dan Faibish; Elizabeth Myers; Lyudmila Spevak; Juliet Compston; Anthony Hodsman; Elizabeth Shane; Robert R Recker; Elizabeth R Boskey; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2009-09       Impact factor: 6.741

View more
  15 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

2.  Polycythemia is associated with bone loss and reduced osteoblast activity in mice.

Authors:  P R Oikonomidou; C Casu; Z Yang; B Crielaard; J H Shim; S Rivella; M G Vogiatzi
Journal:  Osteoporos Int       Date:  2015-12-09       Impact factor: 4.507

3.  Impaired bone formation and osteopenia in heterozygous β(IVSII-654) knockin thalassemic mice.

Authors:  Kanogwun Thongchote; Saovaros Svasti; Mayurachat Sa-ardrit; Nateetip Krishnamra; Suthat Fucharoen; Narattaphol Charoenphandhu
Journal:  Histochem Cell Biol       Date:  2011-06-09       Impact factor: 4.304

Review 4.  Erythropoiesis, anemia and the bone marrow microenvironment.

Authors:  Carl R Walkley
Journal:  Int J Hematol       Date:  2011-01-12       Impact factor: 2.490

Review 5.  Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.

Authors:  Alisa C Dong; Stefano Rivella
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

6.  Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche.

Authors:  Annamaria Aprile; Alessandro Gulino; Mariangela Storto; Isabella Villa; Stefano Beretta; Ivan Merelli; Alessandro Rubinacci; Maurilio Ponzoni; Sarah Marktel; Claudio Tripodo; Maria Rosa Lidonnici; Giuliana Ferrari
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

7.  Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.

Authors:  Rajasekhar N V S Suragani; Sharon M Cawley; Robert Li; Samantha Wallner; Mark J Alexander; Aaron W Mulivor; Sara Gardenghi; Stefano Rivella; Asya V Grinberg; R Scott Pearsall; Ravindra Kumar
Journal:  Blood       Date:  2014-05-02       Impact factor: 22.113

8.  Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease.

Authors:  Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin
Journal:  Kidney Int       Date:  2020-06-20       Impact factor: 10.612

Review 9.  Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease.

Authors:  Annamaria Aprile; Silvia Sighinolfi; Laura Raggi; Giuliana Ferrari
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-11

Review 10.  Erythropoiesis, EPO, macrophages, and bone.

Authors:  Joshua T Eggold; Erinn B Rankin
Journal:  Bone       Date:  2018-03-15       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.